By Tate Fegley (Mises Wire, 11/11/20)

In 2016, presidential candidate Donald Trump denounced the U.S. trade deficit with China and other countries. Trade deficits per se, however, are a poor indicator of the economic health of nations. READ MORE »

By John C. Goodman (Forbes, 10/28/20)

Any drug approved by the FDA to treat one condition may also be used by doctors to treat a different ailment. The freedom to experiment with non-approved drugs has been essential for treating maladies ranging from cancer to Covid-19. READ MORE »

By Gary M. Galles (Mises Wire, 11/5/20)

The 2020 election revealed jaw-dropping levels of “liberal” or progressive bias in the media, but the problem has also long pervaded think tanks and “research” devoted to creating ammunition for the left/progressive conclusions. One example is a 2003 study published by the American Psychological Association that slanders conservatives who uphold principles deemed outdated by left-leaning elites READ MORE »

By Richard K. Vedder (Forbes, 11/24/20)

A recent survey of students from more than 440 colleges and universities found that, with few exceptions, students from non-prestigious schools are more satisfied with their current educational experience than those in the Ivy League. If the current all-remote learning environment continued for years, the prestige schools like Princeton, Stanford, Duke and Northwestern will likely lose their luster and dominant positions on the reputational scale. READ MORE »

By K. Lloyd Billingsley (American Thinker, 10/10/20)

With the signing of AB 979, publicly traded companies headquartered in California are now required to put members of “underrepresented communities” on their boards. Don’t be surprised if fewer corporations decide to set up shop in the Golden State. READ MORE »